InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.2600+0.0600 (+5.00%)

At close: 4:00PM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Relative Strength Index (RSI)

View all chart patterns

Performance Outlook

Previous Close	1.2000
Open	1.1433
Bid	0.0000 x 29200
Ask	0.0000 x 2200
Day's Range	1.0700 - 1.4300
52 Week Range	0.5000 - 10.2000
Volume	8,630,467
Avg. Volume	3,914,569

Market Cap	26.676M
Beta (5Y Monthly)	1.90
PE Ratio (TTM)	N/A
EPS (TTM)	-3.8220
Earnings Date	Aug 11, 2020 - Aug 17, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Simply Wall St.
Will InVivo Therapeutics Holdings (NASDAQ:NVIV) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Companies Like Karoon Energy (ASX:KAR) Are In A Position To Invest In Growth
  Simply Wall St.
- We're Keeping An Eye On Minbos Resources' (ASX:MNB) Cash Burn Rate
  Simply Wall St.
Business Wire
InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.
Business Wire
InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering are expected to be approximately $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.